

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Proposed Single Technology Appraisal (STA)

Romiplostim for the treatment of thrombocytopenic purpura (chronic immune or idiopathic)

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Amgen (Romiplostim) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Age Concern England • Black Health Agency • British Ethnic Health Awareness Foundation • Chinese National Healthy Living Centre • Confederation of Indian Organisations • Counsel and Care • Equalities National Council • Help the Aged • ITP Support Association • Muslim Council of Great Britain • Muslim Health Network • South Asian Health Foundation • Specialised Healthcare Alliance • Splenectomy Trust UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Services to the Elderly • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatric Society • British Society for Haematology • National Blood Service 	<p><u>General</u></p> <ul style="list-style-type: none"> • Age Concern Cymru • Board of Community Health Councils in Wales • British National Formulary • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Public Health Service for Wales • NHS Alliance • NHS Confederation • NHS Purchasing and Supply Agency • NHS Quality Improvement Scotland • Scottish Medicines Consortium <p><u>Comparator manufacturer(s)</u></p> <ul style="list-style-type: none"> • A A H Pharmaceuticals (azathioprine) • Actavis UK (azathioprine, dapsone) • Arrow Generics (azathioprine) • Baxter BioScience (intravenous anti-D immunoglobulin) • Bio Products Laboratory (intravenous normal immunoglobulin) • CSL Behring (intravenous normal immunoglobulin) • Dowelhurst (azathioprine) • Focus Pharmaceuticals (azathioprine) • Generics UK (azathioprine, danazol) • Genus Pharmaceuticals (vinblastine)

National Institute for Health and Clinical Excellence

Consultation on the draft scope and matrix for the appraisal of romiplostim for the treatment of thrombocytopenic purpura (chronic immune or idiopathic)

Issue date: August 2008

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine – Intellectual Disabilities Forum • United Kingdom Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • Eastern and Coastal Kent Teaching PCT • Northamptonshire Teaching PCT • Welsh Assembly Government 	<ul style="list-style-type: none"> • GlaxoSmithKline UK (azathioprine) • Grifols UK (intravenous normal immunoglobulin) • Hospira UK (vinblastine sulphate, vincristine sulphate) • Novartis (cyclosporin) • Pharmacia (cyclophosphamide) • Roche Products (mycophenolate mofetil, rituximab) • Sanofi-Aventis (danazol) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • MRC Clinical Trials Unit • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • Aberdeen HTA Group • National Coordinating Centre for Health Technology Assessment <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> • None <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • None

NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTees AND COMMENTATORS

National Institute for Health and Clinical Excellence

Consultation on the draft scope and matrix for the appraisal of romiplostim for the treatment of thrombocytopenic purpura (chronic immune or idiopathic)

Issue date: August 2008

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the NHS Research and Development Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.

National Institute for Health and Clinical Excellence

Consultation on the draft scope and matrix for the appraisal of romiplostim for the treatment of thrombocytopenic purpura (chronic immune or idiopathic)

Issue date: August 2008

National Institute for Health and Clinical Excellence

Consultation on the draft scope and matrix for the appraisal of romiplostim for the treatment of thrombocytopenic purpura (chronic immune or idiopathic)

Issue date: August 2008